BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

Approval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with uncontrolled or resistant hypertension

BAXFENDY 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline in BaxHTN trial

AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518258445/en/ BAXFENDY logo